GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Cash Conversion Cycle
中文

Trinity Biotech (Trinity Biotech) Cash Conversion Cycle

: 178.97 (As of Sep. 2023)
View and export this data going back to 1995. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Trinity Biotech's Days Sales Outstanding for the three months ended in Sep. 2023 was 90.03.
Trinity Biotech's Days Inventory for the three months ended in Sep. 2023 was 190.73.
Trinity Biotech's Days Payable for the three months ended in Sep. 2023 was 101.79.
Therefore, Trinity Biotech's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2023 was 178.97.


Trinity Biotech Cash Conversion Cycle Historical Data

The historical data trend for Trinity Biotech's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 226.84 240.82 229.27 216.61 197.03

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 174.83 113.73 203.49 186.03 178.97

Competitive Comparison

For the Diagnostics & Research subindustry, Trinity Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech Cash Conversion Cycle Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cash Conversion Cycle falls into.



Trinity Biotech Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Trinity Biotech's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=63.23+178.68-44.88
=197.03

Trinity Biotech's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=90.03+190.73-101.79
=178.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trinity Biotech  (NAS:TRIB) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Trinity Biotech Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.